NASDAQ: REPLReplimune Group Inc Stock Ownership - Who owns Replimune Group?
Insider buying vs selling
Have Replimune Group Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Kapil Dhingra | Director | 2025-12-09 | 3,169 | $1.75 | $5.55kBuy |
| Kapil Dhingra | Director | 2025-12-09 | 3,169 | $10.40 | $32.96kSell |
| Sushil Patel | Chief Executive Officer | 2025-12-02 | 10,000 | $11.13 | $111.30kSell |
| Konstantinos Xynos | Chief Medical Officer | 2025-11-17 | 7,248 | $9.10 | $65.96kSell |
| Christopher Sarchi | Chief Commercial Officer | 2025-11-17 | 5,208 | $9.10 | $47.39kSell |
| Emily Luisa Hill | Chief Financial Officer | 2025-08-15 | 9,154 | $5.37 | $49.16kSell |
| Emily Luisa Hill | Chief Financial Officer | 2025-05-20 | 2,535 | $8.05 | $20.41kSell |
| Christopher Sarchi | Chief Commercial Officer | 2025-05-20 | 3,749 | $8.05 | $30.18kSell |
| Sushil Patel | Chief Executive Officer | 2025-05-20 | 25,105 | $8.06 | $202.35kSell |
| Andrew Schwendenman | Chief Accounting Officer | 2025-05-20 | 3,287 | $8.05 | $26.46kSell |
REPL insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when REPL insiders and whales buy or sell their stock.
REPL Shareholders
What type of owners hold Replimune Group Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Baker Bros Advisors LP | 12.25% | 10,116,095 | $80.63M | Insider |
| Omega Fund IV LP | 11.43% | 9,436,760 | $75.21M | Insider |
| Blackrock Inc | 7.35% | 6,069,633 | $48.37M | Institution |
| Hugo Alexander Slootweg | 5.72% | 4,721,449 | $37.63M | Insider |
| Forbion Capital Fund III Cooperatief Ua | 5.72% | 4,721,449 | $37.63M | Insider |
| Vanguard Group Inc | 4.57% | 3,776,198 | $30.10M | Institution |
| State Street Corp | 4.47% | 3,693,107 | $29.43M | Institution |
| Bain Capital Life Sciences Investors LLC | 3.44% | 2,838,968 | $22.63M | Insider |
| Atlas Venture Fund X LP | 3.01% | 2,486,296 | $19.82M | Insider |
| Erste Asset Management Gmbh | 2.57% | 2,120,000 | $16.90M | Institution |
REPL vs Biotech Stocks
Replimune Group Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.